Paracetamol [acetaminophen] or non-steroidal anti

Transcription

ly
Paracetamol (acetaminophen) or non-steroidal antiinflammatory drugs, alone or combined for pain relief in
acute otitis media in children (Protocol)
Fo
rP
re
vie
w
On
Sjoukes A, Venekamp RP, van de Pol AC, Schilder AGM, Damoiseaux RAMJ
This is a reprint of a Cochrane protocol, prepared and maintained by The Cochrane Collaboration and published in The Cochrane
Library 2015, Issue 3
http://www.thecochranelibrary.com
Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined for pain relief in acute otitis media in
children (Protocol)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
TABLE OF CONTENTS
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
1
1
1
2
3
5
6
7
7
8
8
children (Protocol)
i
ly
.
.
.
.
.
.
.
.
.
.
.
On
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
Fo
rP
re
vie
w
HEADER . . . . . . . . . .
ABSTRACT . . . . . . . . .
BACKGROUND . . . . . . .
OBJECTIVES . . . . . . . .
METHODS . . . . . . . . .
ACKNOWLEDGEMENTS
. . .
REFERENCES . . . . . . . .
APPENDICES . . . . . . . .
CONTRIBUTIONS OF AUTHORS
DECLARATIONS OF INTEREST .
SOURCES OF SUPPORT . . . .
[Intervention Protocol]
ly
Paracetamol (acetaminophen) or non-steroidal antiinflammatory drugs, alone or combined for pain relief in
acute otitis media in children
Alies Sjoukes1 , Roderick P Venekamp2 , Alma C van de Pol1 , Anne GM Schilder3 , Roger AMJ Damoiseaux1
Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands. 2 Department of
Otorhinolaryngology & Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands.
3 evidENT, Ear Institute, Faculty of Brain Sciences, University College London, London, UK
On
1 Julius
Contact address: Roger AMJ Damoiseaux, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht,
Heidelberglaan 100, Utrecht, Utrecht, 3508 GA, Netherlands. [email protected]. [email protected].
w
Editorial group: Cochrane Acute Respiratory Infections Group.
Publication status and date: New, published in Issue 3, 2015.
vie
Citation: Sjoukes A, Venekamp RP, van de Pol AC, Schilder AGM, Damoiseaux RAMJ. Paracetamol (acetaminophen) or non-steroidal
anti-inflammatory drugs, alone or combined for pain relief in acute otitis media in children. Cochrane Database of Systematic Reviews
2015, Issue 3. Art. No.: CD011534. DOI: 10.1002/14651858.CD011534.pub2.
re
ABSTRACT
This is the protocol for a review and there is no abstract. The objectives are as follows:
rP
Our primary objective is to assess the effectiveness of paracetamol (acetaminophen) or NSAIDs, alone or combined, compared with
placebo or no treatment in relieving pain in children with AOM.
Our secondary objective is to assess the effectiveness and safety of NSAIDs as compared with paracetamol in children with AOM.
Fo
BACKGROUND
Description of the condition
Acute otitis media (AOM) is one of the most common childhood
infectious diseases, with an estimated incidence of approximately
300 physician-diagnosed AOM episodes per 1000 person-years
in children aged zero to two years (Liese 2014). By the age of
three years, over 80% of all children have experienced at least
one AOM episode (Teele 1989). Moreover, this condition is an
important cause of antibiotic prescriptions in children (Ashworth
2005; Grijalva 2009). Although severe complications of AOM,
such as mastoiditis, meningitis and intracranial abscess, are rare in
high-income countries, the condition significantly impairs quality
of life for both the child and their parents and is associated with
substantial healthcare resource use and workdays lost for parents
(Greenberg 2003).
AOM is defined by the presence of middle ear effusion together
with acute onset of signs and symptoms of middle ear inflammation (Bluestone 2007; Lieberthal 2013). Cardinal signs of AOM
are bulging of the tympanic membrane or new onset of ear discharge not due to acute otitis externa, while typical AOM symptoms include ear pain and general symptoms of illness such as
fever, irritability and problems feeding and sleeping (Lieberthal
2013). Ear pain due to infection of the middle ear and pressure
building up behind the eardrum is considered the major symp-
children (Protocol)
1
creased risk of inducing bronchospasm in children with asthma
(Rainsford 2009). However, a recent study found no association
between paracetamol or ibuprofen and early childhood asthma
when adjusted for potential confounding (Sordillo 2014). Compared with paracetamol, ibuprofen has a longer duration of action
and as such has the advantage of less frequent dosing (every six
to eight hours versus every four hours for paracetamol) (van den
Anker 2013).
Description of the intervention
How the intervention might work
The exact mechanism of action of paracetamol is not fully understood, but it has been assumed that it acts as a selective inhibitor of
COX-1 and COX-2 in the central nervous system (Bruno 2014).
Unlike NSAIDs, paracetamol does not prevent prostaglandin synthesis by competitive binding to the COX enzyme, but it modulates the COX pathway through its ability to reduce COX activity
(Bruno 2014). Although paracetamol might have some peripheral
effects, its main action appears to be located centrally by inhibiting
prostaglandin synthesis in the brain (Marzuillo 2014). Due to its
minor peripheral effects, paracetamol lacks significant anti-inflammatory activity (van den Anker 2013). When administered intravenously, the peak plasma concentration of paracetamol is reached
earlier than orally or rectally; the peak plasma concentration after
administration of paracetamol as an oral suspension is reached in
around 30 minutes, while for oral tablets and for suppositories it
is approximately 30 to 45 minutes and two to four hours respectively (Marzuillo 2014). For children, the recommended dose of
paracetamol is 10 to 15 mg/kg per dose, every four to six hours
orally (van den Anker 2013).
In contrast to paracetamol, NSAIDs have both central and peripheral effects and can be divided in traditional and selective
COX-2 inhibitors (Bruno 2014). COX-2 inhibition leads to reduced release of pyrogenic molecules in the inflamed cells (mainly
prostaglandin E2) causing the anti-inflammatory and analgesic
effects of NSAIDs (Bruno 2014; Rainsford 2009), while COX1 inhibition is mainly responsible for their gastrointestinal adverse effects (Bruno 2014). Gastrointestinal adverse effects such
as peptic ulcers or bleeding are caused by a dual effect of NSAIDs
on the gastrointestinal tract; the prostaglandin biosynthesis and
maintenance of gastric mucosal integrity (Bruno 2014). Ibuprofen, a non-selective COX inhibitor, is the most commonly used
NSAID in children, with a recommended dose of 5 to 10 mg/kg
per dose every six to eight hours orally, to a maximum dose of 500
mg per day (van den Anker 2013). The relatively low incidence of
serious gastrointestinal adverse effects associated with ibuprofen,
as compared with other NSAIDs, is thought to be the result of
its relatively short half-life (Rainsford 2009). However, ibuprofen, like other NSAIDs, is associated with rare but serious adverse drug reactions of the skin (Stevens-Johnson syndrome), and
the renal (papillary necrosis) and cardiovascular system (Rainsford
2009). Furthermore, ibuprofen has been associated with an in-
With pain being a major symptom of AOM in children, current guidance explicitly recommends the prescription of analgesic
treatment for this condition, irrespective of the use of antibiotics
(Lieberthal 2013). In daily practice, paracetamol and NSAIDs
(ibuprofen) are widely used for relieving pain and fever in children.
Paracetamol is generally considered to be well tolerated and safe
with only a few adverse effects, such as rash and other allergic reactions, when used at therapeutic dosages (Marzuillo 2014; Southey
2009). However, paracetamol has the potential for hepatotoxicity
following overdose (Marzuillo 2014). In general, the safety profile
of ibuprofen is considered to be comparable with that of paracetamol when both drugs are used at the recommended doses and in
the absence of specific contraindications (children with gastrointestinal bleeding or ulcers, congenital heart disease, severe renal
and hepatic disease, concurrent use of anticoagulant and steroid
drugs, and in children below six months of age) (Southey 2009;
van den Anker 2013).
Fo
rP
re
vie
w
On
ly
tom of AOM (Lieberthal 2013), and central to the child’s and
parents’ experience of the illness (Barber 2014; Schechter 2003).
With antibiotics incurring only marginal beneficial effects in children with AOM presenting with mild to moderate disease (Rovers
2006; Venekamp 2013), analgesic treatment, including paracetamol (acetaminophen) and non-steroidal anti-inflammatory drugs
(NSAIDs), is recognised as the cornerstone of the management of
children experiencing AOM (Lieberthal 2013).
Why it is important to do this review
Whilst the effectiveness of topical analgesics in children with AOM
has been reviewed (Foxlee 2006), this has not been done for paracetamol (acetaminophen) or NSAIDs, alone or combined. Previous
Cochrane reviews on paracetamol or NSAIDs (or both) focused either on children with fever due to infectious diseases (Meremikwu
2005; Wong 2013), or included both children and adults with the
common cold (Kim 2013). As such, these reviews did not include
randomised controlled trials (RCTs) on paracetamol or NSAIDs
(or both) for relieving symptoms in childhood AOM. Since AOM
is a specific clinical entity with a high incidence and substantial
societal impact, a comprehensive literature search and systematic
review is warranted to assess 1) the effectiveness of paracetamol
or NSAIDs, alone or combined, compared with placebo or no
treatment in relieving pain in children with AOM and 2) whether
the effects of NSAIDs and paracetamol differ in terms of relieving
pain in children with AOM.
OBJECTIVES
children (Protocol)
2
Our primary objective is to assess the effectiveness of paracetamol
(acetaminophen) or NSAIDs, alone or combined, compared with
placebo or no treatment in relieving pain in children with AOM.
1. NSAIDs versus paracetamol.
Types of outcome measures
ly
Our secondary objective is to assess the effectiveness and safety of
NSAIDs as compared with paracetamol in children with AOM.
Secondary objective
METHODS
Primary outcomes
Types of studies
w
Randomised controlled trials (RCTs) assessing the effectiveness of
paracetamol (acetaminophen) or NSAIDs, alone or combined, in
relieving pain in children with AOM. We will also include trials of paracetamol (acetaminophen) or NSAIDs, alone or combined, for children with fever or upper respiratory tract infections if they allow us to extract subgroup data on pain relief in
children with AOM. We will include trials reporting concurrent
therapy (e.g. co-treatment with oral or topical antibiotics) if they
allow a direct comparison between the intervention and control
group (e.g. paracetamol with concurrent antibiotic therapy versus
placebo with concurrent antibiotic therapy) and if the two groups
are not treated differently. We will define ’not treated differently’
as a maximum of 10% difference in the proportion of children
that received the concurrent therapy between the intervention and
control group.
1. Proportion of children with pain (yes versus no) as rated by
parents/caregivers or children themselves at various time points
(24 hours, two to three days, four to seven days).
2. Adverse effects likely to be related to the use of paracetamol
(acetaminophen) or NSAIDs (or both), such as renal failure/
dysfunction, hepatic failure/dysfunction, gastrointestinal
complaints or bleeding and hypersensitivity reactions such as
erythema, urticaria or anaphylactic shock.
On
Criteria for considering studies for this review
rP
Types of participants
re
vie
Secondary outcomes
Children aged from six months to 16 years with AOM irrespective
of the diagnostic criteria used. We will exclude children with tympanostomy tubes (ventilation tubes or grommets) in place, including those suffering from (acute) tympanostomy tube otorrhoea.
Fo
Types of interventions
We will include trials of paracetamol and NSAIDs delivered orally
or rectally. We will exclude trials of paracetamol or NSAIDS delivered parenterally (intravenous administration).
1. Proportion of children with at most mild pain (defined as
pain less than three points on a 10-point pain scale or less than
30 mm on a 0 to 100 mm visual analogue scale) as rated by
parents/caregivers or patients at various time points (24 hours,
two to three days, four to seven days).
2. Mean time to resolution of pain.
3. Mean pain score at various time points using validated pain
scores.
4. Disease-specific quality of life as measured by a validated
instrument (e.g. AOM Severity of Symptoms Scale (SOS) survey,
OM-6 questionnaire).
5. Mean time to resolution of fever.
6. Proportion of children with fever at various time points.
7. Proportion of children with reconsultations at various time
points.
8. Proportion of children with (delayed) antibiotic
prescriptions at various time points.
9. Total days lost from nursery or school for children because
of AOM.
10. Total days lost from work or education for parents because
of their child’s AOM.
11. Serious complications related to AOM such as mastoiditis
and meningitis.
Primary objective
1. Paracetamol (acetaminophen) versus placebo or no
treatment.
2. NSAIDs versus placebo or no treatment.
3. NSAIDs and background therapy (e.g. paracetamol or
analgesic ear drops) versus background therapy only.
Search methods for identification of studies
We will conduct systematic searches for RCTs. There will be no
language, publication year or publication status restrictions.
children (Protocol)
3
We will resolve any disagreements by discussion.
Assessment of risk of bias in included studies
Two review authors (AS, RPV) will independently assess the
methodological quality of the included trials. We will resolve any
disagreements by discussion. We will assess risk of bias using the
’Risk of bias’ tool as described in Chapter 8 of theCochrane Handbook for Systematic Reviews of Interventions (Handbook 2011). We
will judge the following domains as high, low or unclear risk of
bias:
• sequence generation (selection bias);
• allocation concealment (selection bias);
• blinding of participants and personnel (performance bias);
• blinding of outcome assessment (detection bias);
• incomplete outcome data (attrition bias);
• selective outcome reporting (reporting bias); and
• other sources of bias.
w
Searching other resources
• Participants: study population, number of participants in
each group, patient characteristics including age, gender,
ethnicity.
• Interventions: type of intervention used including timing
and dosage and route of administration.
• Outcomes: primary and secondary outcomes recorded,
time points, complications of AOM and adverse events related to
the interventions.
ly
We will identify published, unpublished and ongoing studies by
searching the following databases from their inception to the current date: the Cochrane Central Register of Controlled Trials
(CENTRAL, current issue), which contains the Cochrane Acute
Respiratory Infections Group’s Specialised Register, MEDLINE,
EMBASE, CINAHL, LILACS and Web of Science.
We will model search strategies for databases on the search strategy designed for MEDLINE (Appendix 1). Where appropriate,
we will combine search strategies with adaptations of the highly
sensitive search strategy designed by The Cochrane Collaboration for identifying RCTs (as described in theCochrane Handbook
for Systematic Reviews of Interventions Version 5.1.0, Box 6.4.b.
(Handbook 2011)). We may include a filter for child studies based
on the work of Boluyt 2008, if the search retrieves an unmanageable number of results.
On
Electronic searches
re
vie
We will search the trials registries World Health Organization
(WHO) International Clinical Trials Registry Platform (ICTRP)
and ClinicalTrials.gov for completed and ongoing trials. We will
scan the reference lists of identified publications for additional
trials and contact trial authors if necessary. In addition, we will
search MEDLINE, TRIP database and The Cochrane Library to
retrieve any published systematic reviews relevant to this review
to scan their citations for additional trials. Furthermore, we will
search the extended abstracts published in the Proceedings from
the International Symposia on Recent Advances in Otitis Media
(grey literature) for any additional trials.
rP
Data collection and analysis
Selection of studies
Fo
Two review authors (AS, RPV) will independently screen the titles
and abstracts obtained from the database searches and citations of
relevant systematic reviews to assess them for potential relevance
for full review. Similarly, two review authors (AS, RPV) will independently review the full text of potentially relevant titles and
abstracts against the pre-defined inclusion and exclusion criteria.
We will resolve any disagreements by discussion.
We will present the results of the ’Risk of bias’ assessment in a
’Risk of bias’ graph and a ’Risk of bias’ summary.
Measures of treatment effect
We will express all dichotomous outcomes as risk ratios (RRs),
odds ratios (ORs), absolute risk differences (aRDs) and number
needed to treat to benefit (NNTB), with accompanying 95% confidence intervals (CIs). We will express continuous outcome variables either as mean differences (MDs) if reported on the same
scale or as standardised mean differences (SMD) if different continuous scales were used, with accompanying 95% CIs.
Unit of analysis issues
In case of cluster-randomised trials, we will use analysis techniques
that take into account the effect of clustering as described in Chapter 16 of theCochrane Handbook for Systematic Reviews of Interventions (Handbook 2011).
Data extraction and management
Two review authors (AS, RPV) will independently extract data
from the included studies using standardised data extraction forms.
We will extract the following information from each trial:
• Study characteristics: setting, design, method of dataanalysis.
Dealing with missing data
We will contact the authors of the included studies in order to
obtain additional information in case of missing data.
In the primary analyses, we will only analyse the available data
according to the intention-to-treat (ITT) principle, i.e. we will
children (Protocol)
4
ly
we will primarily perform a meta-analysis using a wide window
of one to seven days. In secondary analysis, we will use a specific
time point that is used across most studies.
For the comparison of NSAIDs plus background therapy (e.g.
paracetamol or analgesic ear drops) versus background therapy
only, we will primarily perform a meta-analysis of all studies comparing NSAIDs plus background therapy versus background therapy only. In case of significant heterogeneity in pain relief effects
between studies that do and do not include paracetamol in the
background therapy, we will perform an additional analysis by
splitting studies that do and do not include paracetamol in the
background therapy.
We will report the effect estimates as presented by the individual
trials if we decide to refrain from performing a meta-analysis because of clinical diversity.
On
analyse all participants in the group to which they were originally
allocated.
We will assess the impact of incomplete data reporting by performing scenario analyses (best and worst-case scenarios). In bestcase scenario analysis we will count all children who are lost to
follow-up in the intervention group as treatment successes and
count all children lost to follow-up in the control (placebo or no
treatment) group as treatment failures. In contrast, in worst-case
scenario analysis we will count all children who are lost to followup in the intervention group as treatment failures and all children
lost to follow-up in the control group as treatment successes.
In further analysis, we propose to assess the impact of missing
outcome data by using the baseline observation carried forward
approach. In this analysis, we will replace missing outcomes with
the baseline pain value (assuming no pain improvement over time)
to derive a conservative effect estimate (Moore 2012).
Subgroup analysis and investigation of heterogeneity
Assessment of heterogeneity
If possible, we will perform an a priori planned subgroup analysis
for the following subgroups: 1) children below two years of age,
and 2) children two years of age and above, since pain tends to
persist longer in children younger than two years of age as compared with those older than two years (Damoiseaux 2000; Rovers
2007).
vie
w
We will assess the level of clinical diversity between trials by reviewing the included trials for potential differences in study population, interventions used and outcomes measured. We will assess
statistical heterogeneity for each outcome by using the Chi2 test,
with a significance level set at P value < 0.10, and the I2 statistic
(Higgins 2003), with I2 values of 50% or more suggesting substantial heterogeneity.
Sensitivity analysis
Assessment of reporting biases
Data synthesis
rP
re
We will search the Internet and ClinicalTrials.gov (http://
clinicaltrials.gov/) for any relevant study protocols to determine
whether all outcomes listed in the study protocols are published
and whether the outcomes reported were pre-defined. We will assess reporting biases using funnel plots in case of sufficient relevant
trials.
Fo
We will analyse the data according to the ITT principle.
In the absence of significant clinical diversity we will perform a
meta-analysis of included trials. We will use a fixed-effect metaanalysis where no heterogeneity is present. If statistical heterogeneity is detected but unresolved by subgroup analysis, we will
use a random-effects (DerSimonian and Laird) model to provide a
more conservative effect estimate. For both primary and secondary
dichotomous outcomes that are measured at various time points,
To assess the robustness of the review findings, we will perform a
sensitivity analysis in which we will only include trials judged as
low risk of bias. We plan to address in sensitivity analysis whether
the route of administration (oral or rectal) affects the outcome.
In further sensitivity analysis we propose to address whether the
AOM definition used affects the outcome (AOM diagnosis based
solely on symptoms versus AOM diagnosis based on symptoms
and bulging of the tympanic membrane or new onset of ear discharge not due to acute otitis externa). Finally, we propose to assess whether concurrent treatment with antibiotics affects the outcome by analysing studies with and without concurrent antibiotic
therapy separately.
ACKNOWLEDGEMENTS
We gratefully thank Sarah Thorning for designing the search strategy.
children (Protocol)
5
REFERENCES
Bluestone 2007
Bluestone C, Klein J. Definitions, terminology, and
classification. In: Bluestone CD, Klein JO editor(s). Otitis
Media in Infants and Children. 4th Edition. Hamilton,
Canada: BC Decker, 2007:1–19.
Boluyt 2008
Boluyt N, Tjosvold L, Lefebvre C, Klassen TP, Offringa M.
Usefulness of systematic review search strategies in finding
child health systematic reviews in MEDLINE. Archives of
Pediatrics and Adolescent Medicine 2008;162(2):111–6.
Marzuillo 2014
Marzuillo P, Guarino S, Barbi E. Paracetamol: a focus for
the general pediatrician. European Journal of Pediatrics
2014;173(4):415–25.
Meremikwu 2005
Meremikwu M, Marson AG. Paracetamol versus placebo or
physical methods for treating fever in children. Cochrane
Database of Systematic Reviews 2005, Issue 1. [DOI:
10.1002/14651858.CD003676]
Moore 2012
Moore RA, Straube S, Eccleston C, Derry S, Aldington D,
Wiffen P, et al. Estimate at your peril: imputation methods
for patient withdrawal can bias efficacy outcomes in chronic
pain trials using responder analyses. Pain 2012;153(2):
265–8.
Rainsford 2009
Rainsford KD. Ibuprofen: pharmacology, efficacy and
safety. Inflammopharmacology 2009;17(6):275–342.
vie
Bruno 2014
Bruno A, Tacconelli S, Patrignani P. Variability in the
response to non-steroidal anti-inflammatory drugs:
mechanisms and perspectives. Basic and Clinical
Pharmacology and Toxicology 2014;114(1):56–63.
ly
Barber 2014
Barber C, Ille S, Vergison A, Coates H. Acute otitis media in
young children - what do parents say?. International Journal
of Pediatric Otorhinolaryngology 2014;78(2):300–6.
Lieberthal 2013
Lieberthal AS, Carroll AE, Chonmaitree T, Ganiats TG,
Hoberman A, Jackson MA, et al. The diagnosis and
management of acute otitis media. Pediatrics 2013;131(3):
e964–e99.
Liese 2014
Liese JG, Silfverdal SA, Ciaquinto C, Carmona A,
Larcombe JH, Garcia-Sicilia J, et al. Incidence and clinical
presentation of acute otitis media in children aged < 6 years
in European medical practices. Epidemiology and Infection
2014;142(8):1778–88.
On
Ashworth 2005
Ashworth M, Charlton J, Ballard K, Latinovic R, Gulliford
M. Variations in antibiotic prescribing and consultation
rates for acute respiratory infection in UK general practices
1995-2000. British Journal of General Practice 2005;55
(517):603–8.
Kim 2013
Kim SY, Chang YJ, Cho HM, Hwang YW, Moon YS. Nonsteroidal anti-inflammatory drugs for the common cold.
Cochrane Database of Systematic Reviews 2013, Issue 6.
[DOI: 10.1002/14651858.CD006362.pub3]
w
Additional references
re
Damoiseaux 2000
Damoiseaux RA, van Balen FA, Hoes AW, Verheij TJ, de
Melker RA. Primary care based randomised, double blind
trial of amoxicillin versus placebo for acute otitis media in
children aged under 2 years. BMJ 2000;320(7231):350–4.
rP
Foxlee 2006
Foxlee R, Johansson A, Wejfalk J, Dawkins J, Dooley L, Del
Mar C. Topical analgesia for acute otitis media. Cochrane
Database of Systematic Reviews 2006, Issue 3. [DOI:
10.1002/14651858.CD005657]
Fo
Greenberg 2003
Greenberg D, Bilenko N, Liss Z, Shagan T, Zamir O, Dagan
R. The burden of acute otitis media on the patient and the
family. European Journal of Pediatrics 2003;162(9):576–81.
Grijalva 2009
Grijalva CG, Nuorti JP, Griffin MR. Antibiotic prescription
rates for acute respiratory tract infections in US ambulatory
settings. JAMA 2009;302(7):758–66.
Handbook 2011
Higgins JPT, Green S (editors). Cochrane Handbook
for Systematic Reviews of Interventions Version 5.1.0
[updated March 2011]. The Cochrane Collaboration,
2011. Available from www.cochrane-handbook.org.
Higgins 2003
Higgins JPT, Thompson SG, Deeks JJ, Altman DG.
Measuring inconsistency in meta-analysis. BMJ 2003;327
(7414):557–60.
Rovers 2006
Rovers MM, Glasziou P, Appelman CL, Burke P,
McCormick DP, Damoiseaux RA, et al. Antibiotics for
acute otitis media: a meta-analysis with individual patient
data. Lancet 2006;368(9545):1429–35.
Rovers 2007
Rovers MM, Glasziou P, Appelman CL, Burke P,
McCormick DP, Damoiseaux RA, et al. Predictors of pain
and/or fever at 3 to 7 days for children with acute otitis
media not treated initially with antibiotics: a meta-analysis
of individual patient data. Pediatrics 2007;119(3):579–85.
Schechter 2003
Schechter NL. Management of common pain problems in
the primary care pediatric setting. In: Schechter NL, Berde
CB, Yaster M editor(s). Pain in Infants and Adolescents. 2nd
Edition. Philadelphia, PA: Lippincott Williams & Wilkins,
2003:693–706.
Sordillo 2014
Sordillo JE, Scirica CV, Rifas-Shiman SL, Gillman MW,
Bunyavanich S, Camargo CA Jr, et al. Prenatal and infant
children (Protocol)
6
exposure to acetaminophen and ibuprofen and the risk for
wheeze and asthma in children. Journal of Allergy and
Clinical Immunology 2014 Oct 28 [Epub ahead of print].
[DOI: 10.1016/j.jaci.2014.07.065]
van den Anker 2013
Van den Anker JN. Optimising the management of fever
and pain in children. International Journal of Clinical
Practice. Supplement 2013;178:26–32.
Venekamp 2013
Venekamp RP, Sanders S, Glasziou PP, Del Mar CB, Rovers
MM, et al. Antibiotics for acute otitis media in children.
[DOI: 10.1002/14651858.CD000219.pub3]
ly
Southey 2009
Southey ER, Soares-Weiser K, Kleijnen J. Systematic review
and meta-analysis of the clinical safety and tolerability of
ibuprofen compared with paracetamol in paediatric pain
and fever. Current Medical Research and Opinion 2009;25
(9):2207–22.
Wong 2013
Wong T, Stang AS, Ganshorn H, Hartling L, Maconochie
IK, Thomsen AM, et al. Combined and alternating
paracetamol and ibuprofen therapy for febrile children.
[DOI: 10.1002/14651858.CD009572.pub2]
∗
Indicates the major publication for the study
w
On
Teele 1989
Teele DW, Klein JO, Rosner B. Epidemiology of otitis
media during the first seven years of life in children in
greater Boston: a prospective, cohort study. Journal of
Infectious Diseases 1989;160(1):83–94.
vie
APPENDICES
Appendix 1. MEDLINE (Ovid) search strategy
Fo
rP
re
1 exp Otitis Media/
2 otitis media.tw.
3 (aom or ome).tw.
4 (middle ear adj2 (effusion or inflam* or infect*)).tw.
5 glue ear.tw.
6 Respiratory Tract Infections/
7 (respiratory adj2 infection*).tw.
8 ((acute or upper) adj2 respiratory adj2 (symptom* or illness* or infect* or inflam*)).tw.
9 or/1-8
10 Acetaminophen/
11 (paracetamol or acetaminophen or acetominophen or tylenol).tw,nm.
12 exp Anti-Inflammatory Agents, Non-Steroidal/
13 ((nonsteroid* or non-steroid*) adj1 (antiinflam* or anti-inflam*)).tw,nm.
14 (nsaid or nsaids).tw,nm.
15 or/10-14
16 9 and 15
children (Protocol)
7
CONTRIBUTIONS OF AUTHORS
Protocol drafted by: all authors
Screening search results: AS, RPV
Extracting data: AS, RPV
ly
Assessing risk of bias: AS, RPV
Entering data into RevMan: AS, RPV
Interpreting the analysis: all authors
Writing the review: all authors
General advice on the review: all authors
DECLARATIONS OF INTEREST
On
Carrying out analysis: AS, RPV
w
Roderick P Venekamp (RPV) is an Editor of the Cochrane Acute Respiratory Infections Group.
Roger AMJ Damoiseaux (RAMJ) is an Editor of the Cochrane Acute Respiratory Infections Group.
vie
Anne GM Schilder (AGMS) is Joint Co-ordinating Editor of the Cochrane Ear, Nose and Throat Disorders Group. My team at UCL
is supported by an NIHR Research Professorship award to establish an infrastructure and programme of clinical trials in ENT, Hearing
and Balance. My institution has received a grant from GSK for a study on the microbiology of acute tympanostomy tube otorrhoea.
Alies Sjoukes (AS) has no conflicts of interests in the current work.
re
Alma C van de Pol (ACvdP) has no conflicts of interests in the current work.
SOURCES OF SUPPORT
rP
Internal sources
• No sources of support supplied
External sources
Fo
• The Netherlands Organisation for Health Research and Development (ZonMw), Netherlands.
The authors of this review received a grant from the The Netherlands Organisation for Health Research and Development (ZonMw)
to conduct a pragmatic, cluster-randomised clinical trial on pain management for children with AOM in primary care. This trial is
currently ongoing.
• NIHR Research Professorship Award, UK.
Professor Anne Schilder has received an NIHR Research Professorship Award in 2012
children (Protocol)
8

Paracetamol [acetaminophen] or non-steroidal anti

Transcription

Similar documents

Cochrane Standard Author Training Course

Document 6482625

Cochrane Insurance Medicine: A New Resource for Evidence

Investigation of quantum-chemical properties of paracetamol

CAREFUL ANTIBIOTIC USE

Practical Pharmaceutical Analytical Chemistry and Instrumental

Document 6429508

Paracetamol and Back Pain - Chiropractors` Association of Australia

Greenhawk Cochrane - Opening March 7th